LandStar, Inc. Closes Recurring Revenue, High Margin Generating Acquisition in $8 Billion Data Security Market Segment

Third Completed Acquisition in 2018 Brings Monthly Recurring Revenue, EBIT Contribution and Blue-Chip Clientele into Data443   RALEIGH, North Carolina, October 25, 2018 /PRNewswire/ — LandStar, Inc. (OTCPK: LDSR) (“LandStar” or the “Company”), the parent company of Data443™ Risk Mitigation, Inc. (“Data443”), a leading data security and privacy company, announced the closing of the ARALOC™ […]

Flow of Finance Funds Acquisitions and Investment Across the Cannabis Sector

New York, NY – October 25, 2018 – A growing market is supporting a wave of acquisitions and cross-company investments in the cannabis industry.   Significant growth in the cannabis industry is supporting a range of multimillion-dollar investments. Some of these have taken the form of acquisitions, as innovators evolve into established companies. Others are […]

Surge Expands Wireless Market To Serve Active Military and U.S. Veterans

Over 20 million Veterans, Plus Family Members, Qualify For Free Smartphone   Las Vegas, October 25, 2018 – Surge Holdings, Inc. (OTCQB:SURG), the Las Vegas-based Telecom and Fintech software company, announced it’s latest market expansion to the over 20 million active U.S. military, veterans, and immediate family members.   Those eligible for SurgePhone’s Heroes Promotion […]

Denim Price Drop Affected By Athleisure Sports Apparel Popularity

New York NY – October 25, 2018 – A new generation of urban fashion disruptors is continuing to steal market share from major brands, riding the athleisure trend to define new market segments. Major players such as Adidas (OTC:ADDYY) and Foot Locker, Inc.(NYSE:FL), who once dominated the sportswear industry, are now giving way to new […]

Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials

HOUSTON – October 25, 2018 – Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that investigators at […]